Immunome Reports FY Loss and Declining Revenue Amid Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy IMNM?
Source: seekingalpha
- Disappointing Earnings: Immunome's reported GAAP EPS of -$2.43 misses expectations by $0.16, indicating challenges in profitability that could undermine investor confidence and affect stock performance.
- Declining Collaboration Revenue: The company reported collaboration revenue of $6.9 million, a 23.7% year-over-year decline, falling short of the expected $7.7 million, which may negatively impact future liquidity and operational funding.
- Maintaining Strong Buy Rating: Despite the disappointing earnings, Immunome continues to maintain a 'Strong Buy' rating on the successful RINGSIDE trial with Varegacestat, reflecting confidence in its R&D pipeline that may attract long-term investors.
- Proposed Public Offering: Immunome has announced a proposed public offering aimed at raising funds to support its R&D projects, which may exert short-term pressure on the stock price but is expected to enhance financial stability in the long run.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMNM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMNM
Wall Street analysts forecast IMNM stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.540
Low
21.00
Averages
33.20
High
40.00
Current: 21.540
Low
21.00
Averages
33.20
High
40.00
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Opaleye Management Exits Entire Stake in Immunome
- Complete Exit: Opaleye Management sold all 3,185,000 shares of Immunome in Q4 2025 for an estimated $37.30 million, reflecting a full exit that resulted in a 4.92% decrease in its assets under management (AUM).
- Portfolio Shift: The sale eliminated Immunome's representation in Opaleye's portfolio, which previously accounted for 5.3% of AUM, indicating a significant strategic shift that may influence future investment decisions.
- Stock Volatility Impact: While Immunome's stock surged 128.5% over the past year, it has declined approximately 9% over the last two years, highlighting the stock's volatility and prompting Opaleye to reassess its investment strategy.
- Market Outlook: Despite Immunome's strong performance in the past year, analysts recommend that investors consider more stable biotech ETFs to mitigate risk, reflecting a cautious market sentiment towards individual biotech stocks.
See More
Immunome Reports FY Loss and Declining Revenue Amid Public Offering
- Disappointing Earnings: Immunome's reported GAAP EPS of -$2.43 misses expectations by $0.16, indicating challenges in profitability that could undermine investor confidence and affect stock performance.
- Declining Collaboration Revenue: The company reported collaboration revenue of $6.9 million, a 23.7% year-over-year decline, falling short of the expected $7.7 million, which may negatively impact future liquidity and operational funding.
- Maintaining Strong Buy Rating: Despite the disappointing earnings, Immunome continues to maintain a 'Strong Buy' rating on the successful RINGSIDE trial with Varegacestat, reflecting confidence in its R&D pipeline that may attract long-term investors.
- Proposed Public Offering: Immunome has announced a proposed public offering aimed at raising funds to support its R&D projects, which may exert short-term pressure on the stock price but is expected to enhance financial stability in the long run.
See More
Opaleye Management Sells Entire Stake in Immunome for $37.3 Million
- Stake Sale Overview: Opaleye Management sold its entire 3,185,000 shares of Immunome in Q4 2025 for an estimated $37.3 million, resulting in a complete exit from the position and a corresponding $37.3 million drop in quarter-end asset value.
- Portfolio Impact: This transaction reduced Immunome's representation in Opaleye's portfolio from 5.3% to 0%, indicating a total divestment that could influence the fund's future investment strategy.
- Market Performance Analysis: As of February 17, 2026, Immunome shares were priced at $22.69, reflecting a 128.5% increase over the past year, yet a 9% decline over the last two years, highlighting the stock's volatility that may affect investor confidence.
- Investor Strategy Recommendation: Given the volatility of biotech stocks, retail investors are advised to consider biotech ETFs to spread risk, allowing them to benefit from long-term industry growth while mitigating portfolio volatility.
See More
Redmile Group Increases Stake in Immunome
- Share Acquisition: Redmile Group disclosed a purchase of 695,000 shares of Immunome in Q4 2025, with an estimated transaction value of approximately $12.20 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: This acquisition raises Redmile Group's stake in Immunome to 9.05%, highlighting its significance within the investment portfolio and reinforcing long-term investment confidence in Immunome.
- Strong Market Performance: As of February 17, 2026, Immunome shares were priced at $22.69, reflecting a remarkable 120% increase over the past year, significantly outperforming the S&P 500's 13% gain, showcasing market recognition of its potential.
- Funding and R&D Progress: Immunome successfully raised $400 million last year to support its oncology pipeline and plans to file a New Drug Application in Q2 2026, indicating positive clinical advancements and a promising market outlook.
See More
Redmile Group Increases Immunome Holdings
- Share Acquisition: Redmile Group increased its holdings in Immunome by 695,000 shares during Q4 2025, with an estimated trade value of $12.20 million, indicating strong confidence in the company's future prospects.
- Value Growth: By quarter-end, Redmile's total position in Immunome rose to $122.83 million, reflecting a $64.01 million increase driven by both share purchases and stock price appreciation.
- Market Position: Immunome focuses on developing antibody-based therapies for oncology and infectious diseases, with its differentiated pipeline and expertise in antibody engineering providing a competitive edge that attracts investor interest.
- Future Outlook: Immunome plans to file a New Drug Application in Q2 2026, and if its varegacestat receives approval, it could shift market perceptions of its valuation, propelling the company into a commercialization phase.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Impact: While specific stocks are not detailed, such rating changes typically influence investor decisions, thereby directly impacting the stock prices of the companies involved.
- Source of Updates: A complete view of all analyst rating changes can be found on our analyst ratings page, offering a comprehensive understanding of market dynamics.
- Lack of Investment Advice: Although the report provides information on rating changes, it does not offer specific investment advice, leaving investors to make their own judgments.
See More
Opaleye Management Exits Entire Stake in Immunome
- Complete Exit: Opaleye Management sold all 3,185,000 shares of Immunome in Q4 2025 for an estimated $37.30 million, reflecting a full exit that resulted in a 4.92% decrease in its assets under management (AUM).
- Portfolio Shift: The sale eliminated Immunome's representation in Opaleye's portfolio, which previously accounted for 5.3% of AUM, indicating a significant strategic shift that may influence future investment decisions.
- Stock Volatility Impact: While Immunome's stock surged 128.5% over the past year, it has declined approximately 9% over the last two years, highlighting the stock's volatility and prompting Opaleye to reassess its investment strategy.
- Market Outlook: Despite Immunome's strong performance in the past year, analysts recommend that investors consider more stable biotech ETFs to mitigate risk, reflecting a cautious market sentiment towards individual biotech stocks.
See More
Immunome Reports FY Loss and Declining Revenue Amid Public Offering
- Disappointing Earnings: Immunome's reported GAAP EPS of -$2.43 misses expectations by $0.16, indicating challenges in profitability that could undermine investor confidence and affect stock performance.
- Declining Collaboration Revenue: The company reported collaboration revenue of $6.9 million, a 23.7% year-over-year decline, falling short of the expected $7.7 million, which may negatively impact future liquidity and operational funding.
- Maintaining Strong Buy Rating: Despite the disappointing earnings, Immunome continues to maintain a 'Strong Buy' rating on the successful RINGSIDE trial with Varegacestat, reflecting confidence in its R&D pipeline that may attract long-term investors.
- Proposed Public Offering: Immunome has announced a proposed public offering aimed at raising funds to support its R&D projects, which may exert short-term pressure on the stock price but is expected to enhance financial stability in the long run.
See More
Opaleye Management Sells Entire Stake in Immunome for $37.3 Million
- Stake Sale Overview: Opaleye Management sold its entire 3,185,000 shares of Immunome in Q4 2025 for an estimated $37.3 million, resulting in a complete exit from the position and a corresponding $37.3 million drop in quarter-end asset value.
- Portfolio Impact: This transaction reduced Immunome's representation in Opaleye's portfolio from 5.3% to 0%, indicating a total divestment that could influence the fund's future investment strategy.
- Market Performance Analysis: As of February 17, 2026, Immunome shares were priced at $22.69, reflecting a 128.5% increase over the past year, yet a 9% decline over the last two years, highlighting the stock's volatility that may affect investor confidence.
- Investor Strategy Recommendation: Given the volatility of biotech stocks, retail investors are advised to consider biotech ETFs to spread risk, allowing them to benefit from long-term industry growth while mitigating portfolio volatility.
See More
Redmile Group Increases Stake in Immunome
- Share Acquisition: Redmile Group disclosed a purchase of 695,000 shares of Immunome in Q4 2025, with an estimated transaction value of approximately $12.20 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: This acquisition raises Redmile Group's stake in Immunome to 9.05%, highlighting its significance within the investment portfolio and reinforcing long-term investment confidence in Immunome.
- Strong Market Performance: As of February 17, 2026, Immunome shares were priced at $22.69, reflecting a remarkable 120% increase over the past year, significantly outperforming the S&P 500's 13% gain, showcasing market recognition of its potential.
- Funding and R&D Progress: Immunome successfully raised $400 million last year to support its oncology pipeline and plans to file a New Drug Application in Q2 2026, indicating positive clinical advancements and a promising market outlook.
See More
Redmile Group Increases Immunome Holdings
- Share Acquisition: Redmile Group increased its holdings in Immunome by 695,000 shares during Q4 2025, with an estimated trade value of $12.20 million, indicating strong confidence in the company's future prospects.
- Value Growth: By quarter-end, Redmile's total position in Immunome rose to $122.83 million, reflecting a $64.01 million increase driven by both share purchases and stock price appreciation.
- Market Position: Immunome focuses on developing antibody-based therapies for oncology and infectious diseases, with its differentiated pipeline and expertise in antibody engineering providing a competitive edge that attracts investor interest.
- Future Outlook: Immunome plans to file a New Drug Application in Q2 2026, and if its varegacestat receives approval, it could shift market perceptions of its valuation, propelling the company into a commercialization phase.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Impact: While specific stocks are not detailed, such rating changes typically influence investor decisions, thereby directly impacting the stock prices of the companies involved.
- Source of Updates: A complete view of all analyst rating changes can be found on our analyst ratings page, offering a comprehensive understanding of market dynamics.
- Lack of Investment Advice: Although the report provides information on rating changes, it does not offer specific investment advice, leaving investors to make their own judgments.
See More
